Cecilia Pompili, Associate Professor and Thoracic Surgeon focusing on Patient Reported Outcomes Research at the University of Hull, shared a post on X by JAMA Oncology, adding about a paper she co-authored with colleagues published in The Oncologist:
“Our new analysis of resectable NSCLC trials with ICIs and TKIs shows HRQoL is underassessed and underreported. Thanks Massimo Di Maio, Roberto Ferrara, Gabriella Pravettoni, Narjust Florez, Oriana Ciani.
- 48% no assessment
- 14% reported in main paper
- 68% no data available
- Early perioperative/surgery HRQoL rarely captured.”
Title: Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC
Authors: Fabio Salomone, Giorgia Novero, Oriana Ciani, Roberto Ferrara, Alberto Servetto, Narjust Florez, Massimo Di Maio, Gabriella Pravettoni, Cecilia Pompili
You can read the Full Article in The Oncologist.
More posts featuring Cecilia Pompili.
